Lupin Introduces Doxycycline for Injection USP in US Market
Overview
Global pharma major Lupin Limited (Lupin) announced the launch of doxycycline for injection USP, 100 mg/Vial (single-dose vial) in the United States, post approvals from the United States Food and Drug Administration (FDA).
Doxycycline Injection USP
Doxycycline for injection USP is a generic equivalent of Vibramycin for injection, 100 mg/Vial of Pfizer Inc., indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs.
Doxycycline for injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Annual Sale
Doxycycline for injection USP had an estimated annual sale of USD 48 million in the US (IQVIA MAT April 2024).
Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
